Helsinn International Services, an affiliate of the Swiss Pharmaceutical Group, and the Scientific Centre of Monaco (CSM), signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer: clear cell renal cell carcinoma (ccRCC).
ccRCC is diagnosed in over 200,000 patients worldwide each year and the number of people affected continues to increase. Studies investigating neuropilins (NRP) reveal that they are over-expressed in several tumors. However, their inhibition is currently poorly exploited in oncology. This observation provided the rationale for further research into the potential of NRP inhibitors for the treatment of ccRCC.
The research project is conducted by PhD candidate Aurore Dumond, under the supervision of Dr Renaud Grépin and Dr Gilles Pagès.
“We are very pleased to have entered into this partnership with Helsinn as it allows us to pursue a novel area of research in what is an increasingly prevalent form of cancer worldwide”, said Professor Rampal, President of the CSM.
Helsinn, a privately-owned pharmaceutical group with headquarters in Lugano, Switzerland, has an extensive portfolio of marketed cancer care products and a broad development pipeline.